dismiss

The 1st Ever Medical World Americas is in Houston, TX, April 28-30 - Get a Free 1-Day Pass!

Get a Free 3-Day Pass to AAMI 2014 in Philadelphia, May 31-June 2 -- Visit DOTmed, Booth 231

SEARCH

Current Location: DOTmed News > Industry Headlines > This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Industry Headlines

Doc fix bill puts clinical decision support in the spotlight Appropriateness criteria is the new reality.

False positive results: not as bad as you thought But women will still undergo additional breast cancer tests.

ECRI's top 10 patient safety concerns HIT, care coordination, drug shortages top safety list.

FDA clears new CT system from Siemens Ideal for challenging cases.

FDA OKs Shimadzu's new R/F system For a wide variety of exams.

Gov. Jan Brewer signs breast density law Arizona becomes the latest state with inform legislation.

CT can detect arterial plaque for diabetics CCTA is a welcome development.

Goggles that illuminate cancer cells Could they reduce second surgeries?

Philips suspends CT and PET/CT production at Ohio facility Setback for customers and the company.

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

ASTRO 2012: Antidepressant 'rinse' could relieve RT mouth pain

by Brendon Nafziger , DOTmed News Associate Editor
Patients with head and neck cancers who receive radiation therapy often develop painful mouth and throat sores. But an antidepressant mouth rinse might help make the pain more bearable, according to a study presented Monday at ASTRO 2012 in Boston.

The double-blind, phase 3 randomized control trial found a mouthwash made of Doxepin, a tricyclic antidepressant, outperformed a placebo rinse in relieving pain from oral mucositis. Also, two-thirds of patients who tried the Doxeprin wash found it helpful enough to ask for a prescription for it.

Story Continues Below Advertisement

Stretcher pads & mattress discounts for DOTmed users, call (800)448-6163

North America Mattress Corp. offers best pricing for replacement pads and mattresses. Buy direct from the manufacture and save.



"We think it can be used in addition to other (pain relief) agents at this point," study author Dr. Robert C. Miller, a radiation oncologist with Mayo Clinic in Rochester, Minn., told reporters during a press conference Monday. "It's not going to get rid of narcotics, but hopefully it will help people take less."

Doxepin goes by the brand names Adapin, Silenor and Sinequan.

The study, which took place in 26 institutions and involved 155 patients, followed patients for about four hours after receiving their first round of radiation and either a placebo or the Doxepin rinse. For their next fraction, the patients were crossed over to the other rinse.

According to Miller, patients just swishing around a placebo rinse, which was basically just water, experienced pain relief: pain went down an average of 1 point on a 10-point scale. With Doxepin, pain went down about 2 points on average, for a statistically significant difference, he said.

When asked whether they'd like to continue with the Doxepin rinse, 64 percent asked for a prescription, he said.

The Doxepin rinse had no serious side effects, but it did have some mild ones, such as a temporary burning sensation or unpleasant taste. Between 10 and 40 percent of people also experienced drowsiness after using it, and Miller said many patients preferred to take it at night, to help them sleep.

"Compared to placebo, we think Doxepin is an effective agent to reduce pain from oral mucositis," he said.

He also said the drug might be useful in other areas besides oral mucositis pain control - such as for people with nasty canker sores.

The study, "N09C6 (Alliance) - A Phase III, Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy with or without Chemotherapy," was part of a series given at ASTRO on patient outcomes and perspectives on radiation treatment. It was conducted with the Alliance for Clinical Trials in Oncology.

Back to DOTmed News
  Pages: 1

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED